Neurogenic is a clinical-stage diagnostics company developing sensitive immunoassays to assist in the diagnosis of mental disorders. The company has established long-term collaborations with the Weizmann Institute of Science, Rehovot, the Department of Psychiatry, Faculty of Medicine, Tel Aviv University, Tel Aviv, the Beer Yaakov-Ness-Ziona Mental Health Center, Ness Ziona, the Geha Mental Health Center, Petach Tikva, and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Rabin Medical Center, Petah Tikva, Israel to develop a straightforward, sensitive ELISA-based immunoassay to detect the autoimmune Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients suffering from early-onset symptoms of schizophrenia. Neurogenic is now in the final stages of assay optimization. The company is continuing clinical field testing and validation of the assay.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Neurogenic Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Mar 11, 2019
www.synabs.be
Neurogenic and SYnAbs deal for schizophrenia detection